Entera Bio Ltd. [NASDAQ: ENTX] gained 152.50% on the last trading session, reaching $4.04 price per share at the time. The company report on March 12, 2021 that Entera Bio to Report Financial Results for the Year Ended December 31, 2020 on March 18, 2021.
Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the year ended December 30, 2020 on March 18, 2021, before the U.S. financial markets open.
Entera’s management will host a conference call on Thursday, March 18, 2021 at 8:30 a.m. EDT to discuss the results for the quarter. A question-and-answer session will follow Entera’s remarks. To participate on the live call, please dial (855) 547-3865 (US) or (409) 217-8787 (international) and provide the conference ID “5557946” five to ten minutes before the start of the call.
Entera Bio Ltd. represents 18.33 million in outstanding shares, while the company has a total market value of $81.93 million with the latest information. ENTX stock price has been found in the range of $3.97 to $7.87.
If compared to the average trading volume of 526.01K shares, ENTX reached a trading volume of 348912849 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Entera Bio Ltd. [ENTX]:
The Average True Range (ATR) for Entera Bio Ltd. is set at 0.62, with the Price to Sales ratio for ENTX stock in the period of the last 12 months amounting to 409.66. The Price to Book ratio for the last quarter was 13.03.
Trading performance analysis for ENTX stock
Entera Bio Ltd. [ENTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 197.06. With this latest performance, ENTX shares gained by 109.33% in over the last four-week period, additionally plugging by 281.13% over the last 6 months – not to mention a rise of 47.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ENTX stock in for the last two-week period is set at 84.16, with the RSI for the last a single of trading hit 88.89, and the three-weeks RSI is set at 80.75 for Entera Bio Ltd. [ENTX]. The present Moving Average for the last 50 days of trading for this stock 1.59, while it was recorded at 2.02 for the last single week of trading, and 1.46 for the last 200 days.
Entera Bio Ltd. [ENTX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Entera Bio Ltd. [ENTX] shares currently have an operating margin of -4853.39 and a Gross Margin at -89.83. Entera Bio Ltd.’s Net Margin is presently recorded at -4574.15.
Return on Total Capital for ENTX is now -102.57, given the latest momentum, and Return on Invested Capital for the company is -97.44. Return on Equity for this stock declined to -97.98, with Return on Assets sitting at -71.86. When it comes to the capital structure of this company, Entera Bio Ltd. [ENTX] has a Total Debt to Total Equity ratio set at 2.51. Additionally, ENTX Total Debt to Total Capital is recorded at 2.45, with Total Debt to Total Assets ending up at 1.79. Long-Term Debt to Equity for the company is recorded at 1.02, with the Long-Term Debt to Total Capital now at 1.00.
Reflecting on the efficiency of the workforce at the company, Entera Bio Ltd. [ENTX] managed to generate an average of -$449,792 per employee. Receivables Turnover for the company is 0.47 with a Total Asset Turnover recorded at a value of 0.02.Entera Bio Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.70.
Entera Bio Ltd. [ENTX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Entera Bio Ltd. posted -0.12/share EPS, while the average EPS was predicted by analysts to be reported at -0.28/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 57.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ENTX.
An analysis of insider ownership at Entera Bio Ltd. [ENTX]
There are presently around $3 million, or 8.80% of ENTX stock, in the hands of institutional investors. The top three institutional holders of ENTX stocks are: KNOLL CAPITAL MANAGEMENT, LP with ownership of 1,741,363, which is approximately 0% of the company’s market cap and around 41.20% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 72,186 shares of the stock with an approximate value of $0.12 million in ENTX stocks shares; and VIRTU FINANCIAL LLC, currently with $50000.0 in ENTX stock with ownership of nearly New of the company’s market capitalization.
Positions in Entera Bio Ltd. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 2 institutional holders increased their position in Entera Bio Ltd. [NASDAQ:ENTX] by around 103,500 shares. Additionally, 3 investors decreased positions by around 151,004 shares, while 2 investors held positions by with 1,603,229 shares. The mentioned changes placed institutional holdings at 1,857,733 shares, according to the latest SEC report filing. ENTX stock had 2 new institutional investments in for a total of 103,500 shares, while 2 institutional investors sold positions of 143,636 shares during the same period.